Contact us

About
About
Shield Therapeutics is a well-funded, high potential, commercial stage specialty-pharma company. We pride ourselves on providing solutions to unmet medical needs and delivering value to our shareholders.
Explore section
Our Strategy and Values

People
Lead Products
Lead Products
Shield has a rare opportunity to build an integrated, highly profitable specialty pharma business. In this section you can learn more about our lead product, and about our second asset.
Explore section
Feraccru^® / Accrufer^®
Pipeline product candidates
Partnering
Investors
Investors
Shield is well positioned to become a fast growing, independent, international specialty pharmaceutical company due to the strength of its products and team, and with great thanks to all of our supportive shareholders.
RNS News

Share Price Summary

Corporate Governance

AIM Rule 26

Video and Audio

Investor Contacts

Corporate Documents

Presentations

Advisor Contacts

Financial Calendar

Analyst Coverage
News
Events

Interim Report for the Six Months Ended 30 June 2018

19 Sep 2018

Shield Therapeutics plc, today announces its unaudited interim results for the six months ended 30 June 2018.

For further details please see the attachment provided below.

STX_Interim report_30Jun18